Cladribine regimen for treating multiple sclerosis
US8377903B2 · kind B2 · utility
5Cited by
2References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2010 |
| Grant date | Feb 19, 2013 |
| Priority date | — |
| Expiry date | Oct 2, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.